GSK2189242A (GSK)

The pneumococcal protein candidate vaccine, identified by the development code **GSK2189242A**, is an investigational protein subunit vaccine developed by GSK. Unlike traditional pneumococcal conjugate vaccines (PCVs) that target the capsular polysaccharide, this vaccine is designed to provide serotype-independent protection by targeting highly conserved surface proteins of *Streptococcus pneumoniae*. The formulation contains two primary recombinant antigens: **detoxified pneumolysin (dPly)**, a modified version of the cholesterol-dependent cytolysin virulence factor, and **pneumococcal histidine triad protein D (PhtD)**, which is involved in metal ion homeostasis and bacterial adhesion. These antigens are adsorbed onto an aluminum-based adjuvant (alum). The vaccine has been evaluated in Phase I and Phase II clinical trials, including studies in infants and healthy young adults, to assess its safety, reactogenicity, and ability to induce broad immunity against invasive pneumococcal disease and pneumonia.

Other names

pneumococcal protein candidate vaccinedPly-PhtD vaccineGSK pneumococcal protein vaccinedetoxified pneumolysin and pneumococcal histidine triad protein D vaccine